Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811764 | 0.88 | EPHX2 (0.31) | EPHX2 | |
| SCHEMBL19955142 | 0.79 | IL1B (0.34) | — | |
| SCHEMBL17811766 | 0.78 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL17815707 | 0.77 | APLNR (0.42) | APLNR | |
| SCHEMBL20820265 | 0.77 | APLNR (0.42) | APLNR | |
| SCHEMBL17811801 | 0.77 | EPHX2 (0.32) | EPHX2 | |
| SCHEMBL12305130 | 0.77 | — | — | |
| SCHEMBL20667438 | 0.73 | CYP1A2 (0.39) | — | |
| SCHEMBL12459488 | 0.71 | CYP1A2 (0.43) | — | |
| SCHEMBL20199399 | 0.70 | APLNR (0.44) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-11-09 | — | — | US | disclosed |
| WO-2021176366-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-09-10 | — | — | WO | disclosed |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | TRPV1, TRPA1, KCNJ2 | APLNR 334/4885EPHX2 2425/4885 |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | APLNR 334/4885EPHX2 2425/4885 |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | APLNR 4863/4885EPHX2 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.